General Information of the Drug (ID: ferrodrug0444)
Name
Cetuximab
Status
Approved
Drug Type
Antibody
TTD Drug ID
D0N5OV
Full List of Ferroptosis Target Related to This Drug
Nuclear factor erythroid 2-related factor 2 (NFE2L2)
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Marker/Suppressor
Responsed Disease Colorectal cancer ICD-11: 2B91
Responsed Regulator Mitogen-activated protein kinase 14 (MAPK14) Driver
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
DLD-1 cells Colon adenocarcinoma Homo sapiens CVCL_0248
LoVo cells Colon adenocarcinoma Homo sapiens CVCL_0399
SW480 cells Colon adenocarcinoma Homo sapiens CVCL_0546
In Vivo Model
The DLD-1 cell suspension (4 x 106 cells/200 ul) was injected subcutaneously into the right dorsal flank of 5-week-old male BALB/c nude mice (Charles River, China). The mice were randomly divided into four groups (5 mice/group): 1) the control group, 2) the RSL3 group, 3) the cetuximab group, and 4) the RSL3 + cetuximab group. Both RSL3 (5 mg/kg) and cetuximab (13 mg/kg) were administered by intraperitoneal injection in a volume of 100 ul once per day. The tumour volume was calculated as 0.5 x length x width2. After 17 days of treatment, the mice were sacrificed, and the tumours were removed. Then, tumour tissue obtained from the different treated groups was subjected to western blotting and immunohistochemical experiments.

    Click to Show/Hide
Response regulation Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant Colorectal cancer (CRC) cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.
Heme oxygenase 1 (HMOX1)
In total 1 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [1]
Target for Ferroptosis Suppressor
Responsed Disease Colorectal cancer ICD-11: 2B91
Responsed Regulator Mitogen-activated protein kinase 14 (MAPK14) Driver
Pathway Response Ferroptosis hsa04216
Fatty acid metabolism hsa01212
Cell Process Cell ferroptosis
Cell proliferation
In Vitro Model HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
DLD-1 cells Colon adenocarcinoma Homo sapiens CVCL_0248
LoVo cells Colon adenocarcinoma Homo sapiens CVCL_0399
SW480 cells Colon adenocarcinoma Homo sapiens CVCL_0546
In Vivo Model
The DLD-1 cell suspension (4 x 106 cells/200 ul) was injected subcutaneously into the right dorsal flank of 5-week-old male BALB/c nude mice (Charles River, China). The mice were randomly divided into four groups (5 mice/group): 1) the control group, 2) the RSL3 group, 3) the cetuximab group, and 4) the RSL3 + cetuximab group. Both RSL3 (5 mg/kg) and cetuximab (13 mg/kg) were administered by intraperitoneal injection in a volume of 100 ul once per day. The tumour volume was calculated as 0.5 x length x width2. After 17 days of treatment, the mice were sacrificed, and the tumours were removed. Then, tumour tissue obtained from the different treated groups was subjected to western blotting and immunohistochemical experiments.

    Click to Show/Hide
Response regulation Our work reveals that cetuximab enhances the cytotoxic effect of RSL3 on KRAS mutant Colorectal cancer (CRC) cells and that cetuximab enhances RSL3-induced ferroptosis by inhibiting the Nrf2/HO-1 axis through the activation of p38 MAPK.
Unspecific Target
In total 2 item(s) under this Target
Experiment 1 Reporting the Ferroptosis-centered Drug Act on This Target [2]
Responsed Disease Colorectal cancer ICD-11: 2B91
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell Process Cell ferroptosis
In Vitro Model DiFi cells Colorectal carcinoma Homo sapiens CVCL_6895
CCK-81 cells Colon adenocarcinoma Homo sapiens CVCL_2873
C75 cells Colon adenocarcinoma Homo sapiens CVCL_5248
In Vivo Model
The PDX models used in this study were derived from patients (CRC0078 and CRC0121) carrying a quadruple wild-type (KRAS,NRAS,BRAF, andPIK3CA) colorectal tumor. Established tumors (average volume 300 or 500 mm3, as indicated) were treated with the following regimens, either single-agent or in combination: VitC (Sigma, 4 g/kg, intraperitoneal, daily-5 days per week), cetuximab (Merck, 10 mg/kg, intraperitoneal, twice weekly).

    Click to Show/Hide
Response regulation Cetuximab blunts carbohydrate metabolism by blocking glucose uptake and glycolysis, beyond promoting slow but progressive ROS production. In parallel, Vitamin C disrupts iron homeostasis and further increases ROS levels ultimately leading to ferroptosis. Considering that high-dose VitC is known to be safe in cancer patients, this findings might have clinical impact on colorectal cancer patients treated with anti-EGFR therapies.
Experiment 2 Reporting the Ferroptosis-centered Drug Act on This Target [3]
Responsed Disease Colorectal cancer ICD-11: 2B91
Pathway Response Fatty acid metabolism hsa01212
Ferroptosis hsa04216
Cell adhesion molecules hsa04514
Cell Process Cell ferroptosis
Cell proliferation
Cell migration
In Vitro Model HCT 116 cells Colon carcinoma Homo sapiens CVCL_0291
LoVo cells Colon adenocarcinoma Homo sapiens CVCL_0399
Caco-2 cells Colon adenocarcinoma Homo sapiens CVCL_0025
In Vivo Model
5-week-old female BALB/c nude were purchased from Shanghai Slac Laboratory Animal Co., Ltd. HCT116-luc cells were digested and washed by cold PBS for three times, and the final concentration was 2.5 x 106/ml in cold PBS. A volume of 100 ul cell suspension was injected subcutaneously into right dorsal flank of mice. When the tumor tissue in the subcutaneous was macroscopic, the tumor tissues were dissected and embedded into the mesentery of mice.

    Click to Show/Hide
Response regulation b-elemene in combination with cetuximab was shown to induce iron-dependent reactive oxygen species (ROS) accumulation, glutathione (GSH) depletion, lipid peroxidation, upregulation of HO-1 and transferrin, and downregulation of negative regulatory proteins for ferroptosis (GPX4, SLC7A11, FTH1, glutaminase, and SLC40A1) in KRAS mutant colorectal cancer cells.
References
Ref 1 Cetuximab promotes RSL3-induced ferroptosis by suppressing the Nrf2/HO-1 signalling pathway in KRAS mutant colorectal cancer. Cell Death Dis. 2021 Nov 13;12(11):1079. doi: 10.1038/s41419-021-04367-3.
Ref 2 Vitamin C Restricts the Emergence of Acquired Resistance to EGFR-Targeted Therapies in Colorectal Cancer. Cancers (Basel). 2020 Mar 14;12(3):685. doi: 10.3390/cancers12030685.
Ref 3 Combinative treatment of -elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation. Theranostics. 2020 Apr 6;10(11):5107-5119. doi: 10.7150/thno.44705. eCollection 2020.